Vilchez, Regis A.,Rodrigues Jr., Lino X.,Bernstein, Barry M.,Podsadecki, Thomas J.,Brun, Scott C.,Cohen, Daniel E.,Menon, Rajeev M.,Khatri, Amit,Mensing, Sven,Dutta, Sandeep,Awni, Walid M.,Dumas, Em
申请号：
AU2016285578
公开号：
AU2016285578A1
申请日:
2016.06.28
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1 b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1 b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.
